Advertisement

Pathology & Oncology Research

, Volume 25, Issue 2, pp 817–818 | Cite as

JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients

  • Matthew K. SteinEmail author
  • Lindsay K. Morris
  • Mike G. Martin
Letter to the Editor

Main Text

Non-receptor tyrosine kinase (nRTK) pathways are aberrantly activated in cancer, and mutations in nRTKs have potential therapeutic and prognostic importance. Consisting of 10 families, the 32 known human nRTKs each include a TKD made of N and C-terminal lobes necessary for catalytic activity, as well as varying regulatory regions including Src homology 2 (SH2) and 3 (SH3), and in the case of the Janus kinases a PSKD which is also bi-lobed [1]. Tumor profiling with NGS enables the entire coding sequence of numerous genes to be evaluated, thus facilitating the identification of novel nsSNPs in nRTKs.

We reviewed advanced breast, colon and lung cancer patients treated at West Cancer Center (Memphis, Tennessee) from 2013 to 2015 who received tumor profiling including NGS with a 592 cancer-related gene panel from Caris Life Sciences (Phoenix, Arizona). Caris NGS searched 14 nRTKs: ABL1, ABL2, AKT1, AKT2, AKT3, BTK, JAK1, JAK2, JAK3, SRC, CDK4, CDK6, CDK12, PIK3CA. All mutations...

References

  1. 1.
    Lupardus PJ, Ultsch M, Wallweber H et al (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A 111:8025–8030CrossRefGoogle Scholar
  2. 2.
    Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS (2010) Sunyaev SR. Nat Methods 7(4):248–249CrossRefGoogle Scholar
  3. 3.
    Canté-Barrett K, Uitdehaag JC, Meijerink JP (2016) Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains. Haematologica 101(5):e189–e191CrossRefGoogle Scholar
  4. 4.
    Perez C, Gonzalez-Rincon J, Onaindia A et al (2015) Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica 100(11):e450–e453CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  1. 1.West Cancer CenterMemphisUSA
  2. 2.Department of Hematology and OncologyUniversity of Tennessee Health Science CenterMemphisUSA
  3. 3.College of MedicineUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations